CincyTech-backed Eikonoklastes Therapeutics receives FDA approval for first-in-class ALS treatment

Eikonoklastes Therapeutics, a Cincinnati biotech startup developing a first-in-class treatment for ALS, otherwise known as Lou Gehrig’s Disease, received FDA approval.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.